The Experts in Animal Health

print version

Brakke Consulting’s
Animal Health News & Notes for March 14, 2014
Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon DVM MBA
Brakke Consulting news
Pain Management Products report
Veterinary practice management
earnings news
Big Heart Pet Brands
Krka Group
other news
Bock VetPharma
Cooperative Resources International
HQ Specialty
Minitube of America
Procter & Gamble Pet Care
SeQuent Scientific
Shasun Pharmaceuticals
West Agro
WG Critical Care

Pain management is one of the leading topics in veterinary medicine today.  Brakke Consulting’s annual report on Pain Management Products for Dogs and Cats includes such valuable information as:
  – overview of acute and chronic pain in small animals
  – review of new products
  – estimates of US sales and prices of leading products
  – pain management products in development
  – review of nutritional supplements used for chronic pain
  – review of therapeutic diets for joint care
  – 2014 survey of 200 small animal veterinarians regarding use of pain management products
Pain Management Products for Dogs and Cats 2014 can be purchased for $4,995 if ordered by March 31, 2014.  The report will be completed in April.  Questions about the study can be answered by project manager Lynn Fondon, DVM, MBA at 972-243-4033, or email
> Slovenian generic pharmaceutical manufacturer Krka Group recorded animal health sales of EUR 42.6 million ($59.2 million) in 2013, unchanged compared to 2012. (Animal Pharm)
> Big Heart Pet Brands (formerly known as Del Monte Corporation) reported financial results for the third fiscal quarter 2014. Pet Products net sales increased 9% to $576 million primarily driven by volume from the recently acquired Natural Balance brand. Net income was $34.2 million, an increase of 21% compared to the comparable quarter in the prior year. (company website)
> Bayer Animal Health division announced the launch of eight new flea and/or tick treatment and control solutions to be sold at pet specialty retail stores. The new products, part of the Advantage product line, include Treatment Spray for dogs, Treatment Spray for cats, Treatment Shampoo for dogs, Treatment Shampoo for cats, Household Spot & Crevice Spray, Carpet & Upholstery Spot Spray, Household Fogger, and Yard & Premise Spray. ( 
> Virbac Corporation announced that Paul Hays has been promoted to President and CEO of North America, effective April 1, 2014, succeeding Dr. Erik Martinez. In his new role, Hays will oversee all corporate functions for Virbac North America and be responsible for the growth and profitability of both US and Canadian operations. (company press release)
> Phibro Animal Health announced it has filed for an initial public offering (IPO), which could be worth up to $230 million. Phibro’s minority stockholder Mayflower Limited Partnership will be a selling stockholder in the IPO; newly-issued shares will also be sold by the company. The Bendheim family is not selling any of its shares in the offering and will retain a controlling stake in Phibro. (Animal Pharm)  
> Sergeant’s Pet Care Products, Inc., announced the launch of two flea and tick products at the 2014 Global Pet Expo: PetArmor Plus IGR for fleas and ticks and FastCaps (nitenpyram) for fleas. PetArmor Plus IGR contains fipronil and Novaluron, an Insect Growth Regulator (IGR). FastCaps contains the same active ingredient found in Novartis’ Capstar. (
> Innovacyn Inc. announced the launch of Vetericyn Feline Hydrogel Wound & Skin Care spray. The immediate-acting, one-step product is non-toxic, steroid-free, antibiotic-free, and does not contain alcohol or tea tree oils. The hydrogel can be used to clean wounds and manage cuts, minor burns, scratches, hot spots and skin irritations. (company press release) 
> Bock VetPharma announced the launch of ConSeal-AlH easy chews with 200mg of Aluminum Hydroxide. ConSeal-AlH is a phosphorus binder for felines with chronic kidney problems. (company press release)
> WG Critical Care, LLC, announced that it and its affiliate, HQ Specialty Pharma Corporation, signed an agreement with West Agro, Inc. to acquire the rights for Quartermaster Suspension (penicillin-dihydrostreptomycin in oil), FDA approved, for intramammary use to reduce the frequency of existing infection and to prevent new infections with Staphylococcus aureus in dry cows. Financial terms were not disclosed. (Vet Advantage) 
> Jaguar Animal Health submitted Investigational New Animal Drug Applications to the FDA’s Center for Veterinary Medicine for use of its lead candidate SP-303  to treat watery diarrhea in dogs, cats and horses. SP-303 is isolated and purified from Croton lechleri, a medicinal plant sustainably harvested from the Peruvian rain forest. SP-303 is also under submission for MUMS designation for use in dogs with chemotherapy-induced diarrhea. (Animal Pharm) 
> Cooperative Resources International (CRI) announced the acquisition of the primary assets of MofA, formerly known as Minitube of America. MofA is one of the world’s leaders in the development, manufacturing and marketing of artificial insemination and embryo transfer products and technologies for the porcine, bovine, equine and canine industries. Financial terms were not disclosed. (Vet Advantage)
> UK  Novartis Animal Health UK has announced a strategic partnership with Procter & Gamble (P&G) Pet Care. As part of the arrangement, the Novartis sales team will be detailing P&G’s Iams and Eukanuba products to veterinary practices beginning April 1, 2014 in the UK and at a later stage in Ireland. (Vet Advantage)
> INDIA  Shasun Pharmaceuticals Ltd announced a Joint Venture agreement with SeQuent Scientific Ltd to develop, manufacture and sell veterinary products including active pharmaceutical ingredients (API) and formulations in the global market. (
> UK  Dechra Veterinary Products announced the UK launch of Buprenodale (buprenorphine) opioid analgesic for cats, dogs and horses. Buprenodale is presented in a 10ml multi-dose vial. (
> NORWAY – ISA   Norway has reported a large outbreak of infectious salmon anemia (ISA) at two different aquaculture complexes in the Nordland peninsula. Movement controls have been implemented and premises disinfected. A vaccination strategy has not been applied. (Animal Pharm)
> US – ANTIBIOTIC USE   Members of the Animal Health Institute (AHI) and the Generic Animal Drug Alliance (GADA) announced their written commitments to align all affected products with the FDA’s policy on judicious use of antibiotics. Under the policy, the growth promotion uses of medically important compounds will be phased out and veterinary oversight of the use of therapeutic products will be phased in. (association press release)
> SCOTLAND – STEM CELL RESEARCH  Researchers in Scotland have produced working nerve cells from horse stem cells for the first time. They believe this could be the first step towards new treatments for neurological conditions that affect horses such as equine grass sickness and conditions similar to motor neuron disease in humans. The development could also provide a platform to test stem-cell based therapies before clinical studies in humans. (Animal Pharm)

Is your company is looking for new ways to increase your exposure to current and prospective veterinary customers? Practice Management Consultant Jessica Lee of Brakke Consulting speaks on a wide array of topics that can provide added value to your veterinary customers.

Jessica will be speaking at the American Animal Hospital Association Yearly Conference in Nashville, TN on Sunday, March 23. Her topics include Preventive Care Plans and Pet Insurance & Other Alternative Financing Options.

For more information on how to book Jessica for speaking engagements, contact her at or 919-444-3279.


A couple of stories in this week’s newsletter reflect the continued expansion of product offerings in the OTC trade that at one time were only available through veterinarians. This product migration has been occurring for the past few years and it is likely to accelerate unless veterinarians become better marketers of their services and products available to their clients.

The announcement this week that Phibro Animal Health has filed for an initial public offering (IPO) is another indication of values the financial community and investors are seeing in animal health companies. There were several successful IPO’s of animal health companies in 2013 and we expect an increasing flow of these types of transactions in the coming months.
As we noted in our recent Animal Health Industry Overview, the ownership of animal health companies is changing from pharmaceutical and privately owned companies to the publicly traded stand-alone companies. Whether or not this transfer of ownership to unlock the value of the animal health business is a positive or negative for the industry will be determined in the next two to three years.

Have a great weekend!!
Ron Brakke

This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at
Brakke Consulting, Inc.
12005 Ford Rd., Suite 530
Dallas, TX  75234    USA

en_USEnglish (United States)